Publications by the researcher in collaboration with Santiago Moreno Guillén (95)

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  2. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

  3. Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir

    Drug design, development and therapy, Vol. 16, pp. 827-841

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment

    AIDS (London, England), Vol. 35, Núm. 8, pp. 1283-1293

  3. Late presentation for HIV remains a major health issue in Spain: Results from a multicenter cohort study, 2004–2018

    PLoS ONE, Vol. 16, Núm. 4 April

  4. Redefining therapeutic success in HIV patients: An expert view

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518

2020

  1. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study

    AIDS Research and Therapy, Vol. 17, Núm. 1

  2. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

  3. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

  4. The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations

    The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 5, pp. 1294-1300

2019

  1. Correction: Awareness, knowledge, use, willingness to use and need of Pre-Exposure Prophylaxis (PrEP) during World Gay Pride 2017 (PLoS ONE (2017) 13: 10 (e0204738) DOI: 10.1371/journal.pone.0204738)

    PLoS ONE

  2. HIV pre-exposure prophylaxis (PrEP) in Spain: political and administrative situation

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 10, pp. 656-660

2018

  1. Awareness, knowledge, use, willingness to use and need of Pre-Exposure Prophylaxis (PrEP) during World Gay Pride 2017

    PLoS ONE, Vol. 13, Núm. 10

  2. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

    American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522

  3. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  4. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337

2017

  1. Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 35, Núm. 6, pp. 377-383

  2. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

  3. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253